395 related articles for article (PubMed ID: 38160327)
1. The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023.
Wang FH; Zhang XT; Tang L; Wu Q; Cai MY; Li YF; Qu XJ; Qiu H; Zhang YJ; Ying JE; Zhang J; Sun LY; Lin RB; Wang C; Liu H; Qiu MZ; Guan WL; Rao SX; Ji JF; Xin Y; Sheng WQ; Xu HM; Zhou ZW; Zhou AP; Jin J; Yuan XL; Bi F; Liu TS; Liang H; Zhang YQ; Li GX; Liang J; Liu BR; Shen L; Li J; Xu RH
Cancer Commun (Lond); 2024 Jan; 44(1):127-172. PubMed ID: 38160327
[TBL] [Abstract][Full Text] [Related]
2. The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021.
Wang FH; Zhang XT; Li YF; Tang L; Qu XJ; Ying JE; Zhang J; Sun LY; Lin RB; Qiu H; Wang C; Qiu MZ; Cai MY; Wu Q; Liu H; Guan WL; Zhou AP; Zhang YJ; Liu TS; Bi F; Yuan XL; Rao SX; Xin Y; Sheng WQ; Xu HM; Li GX; Ji JF; Zhou ZW; Liang H; Zhang YQ; Jin J; Shen L; Li J; Xu RH
Cancer Commun (Lond); 2021 Aug; 41(8):747-795. PubMed ID: 34197702
[TBL] [Abstract][Full Text] [Related]
3. The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer.
Wang FH; Shen L; Li J; Zhou ZW; Liang H; Zhang XT; Tang L; Xin Y; Jin J; Zhang YJ; Yuan XL; Liu TS; Li GX; Wu Q; Xu HM; Ji JF; Li YF; Wang X; Yu S; Liu H; Guan WL; Xu RH
Cancer Commun (Lond); 2019 Mar; 39(1):10. PubMed ID: 30885279
[TBL] [Abstract][Full Text] [Related]
4. [Updates and interpretation on NCCN clinical practice guidelines for gastric cancer 2017 version 5].
Qiu H; Zhou Z
Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Feb; 21(2):160-164. PubMed ID: 29492914
[TBL] [Abstract][Full Text] [Related]
5. Chinese Society of Clinical Oncology (CSCO) Breast Cancer Guidelines 2022.
Jiang Z; Li J; Chen J; Liu Y; Wang K; Nie J; Wang X; Hao C; Yin Y; Wang S; Yan M; Wang T; Yan Y; Chen X; Song E;
Transl Breast Cancer Res; 2022; 3():13. PubMed ID: 38751537
[TBL] [Abstract][Full Text] [Related]
6. The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinoma.
Tang LL; Chen YP; Chen CB; Chen MY; Chen NY; Chen XZ; Du XJ; Fang WF; Feng M; Gao J; Han F; He X; Hu CS; Hu DS; Hu GY; Jiang H; Jiang W; Jin F; Lang JY; Li JG; Lin SJ; Liu X; Liu QF; Ma L; Mai HQ; Qin JY; Shen LF; Sun Y; Wang PG; Wang RS; Wang RZ; Wang XS; Wang Y; Wu H; Xia YF; Xiao SW; Yang KY; Yi JL; Zhu XD; Ma J
Cancer Commun (Lond); 2021 Nov; 41(11):1195-1227. PubMed ID: 34699681
[TBL] [Abstract][Full Text] [Related]
7. Heterogeneity and Adjuvant Therapeutic Approaches in MSI-H/dMMR Resectable Gastric Cancer: Emerging Trends in Immunotherapy.
Wu H; Ma W; Jiang C; Li N; Xu X; Ding Y; Jiang H
Ann Surg Oncol; 2023 Dec; 30(13):8572-8587. PubMed ID: 37667098
[TBL] [Abstract][Full Text] [Related]
8. Current treatment and recent progress in gastric cancer.
Joshi SS; Badgwell BD
CA Cancer J Clin; 2021 May; 71(3):264-279. PubMed ID: 33592120
[TBL] [Abstract][Full Text] [Related]
9. Is Adjuvant Chemotherapy Necessary for Patients with Deficient Mismatch Repair Gastric Cancer?-Autophagy Inhibition Matches the Mismatched.
Tsai CY; Lin TA; Huang SC; Hsu JT; Yeh CN; Chen TC; Chiu CT; Chen JS; Yeh TS
Oncologist; 2020 Jul; 25(7):e1021-e1030. PubMed ID: 32058649
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study.
André T; Tougeron D; Piessen G; de la Fouchardière C; Louvet C; Adenis A; Jary M; Tournigand C; Aparicio T; Desrame J; Lièvre A; Garcia-Larnicol ML; Pudlarz T; Cohen R; Memmi S; Vernerey D; Henriques J; Lefevre JH; Svrcek M
J Clin Oncol; 2023 Jan; 41(2):255-265. PubMed ID: 35969830
[TBL] [Abstract][Full Text] [Related]
11. Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of immunotherapy in patients with DNA mismatch repair deficient (dMMR) tumors, third edition.
Mishima S; Naito Y; Akagi K; Hayashi N; Hirasawa A; Hishiki T; Igarashi A; Ikeda M; Kadowaki S; Kajiyama H; Kato M; Kenmotsu H; Kodera Y; Komine K; Koyama T; Maeda O; Miyachi M; Nishihara H; Nishiyama H; Ohga S; Okamoto W; Oki E; Ono S; Sanada M; Sekine I; Takano T; Tao K; Terashima K; Tsuchihara K; Yatabe Y; Yoshino T; Baba E
Int J Clin Oncol; 2023 Oct; 28(10):1237-1258. PubMed ID: 37599324
[TBL] [Abstract][Full Text] [Related]
12. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS.
Muro K; Van Cutsem E; Narita Y; Pentheroudakis G; Baba E; Li J; Ryu MH; Zamaniah WIW; Yong WP; Yeh KH; Kato K; Lu Z; Cho BC; Nor IM; Ng M; Chen LT; Nakajima TE; Shitara K; Kawakami H; Tsushima T; Yoshino T; Lordick F; Martinelli E; Smyth EC; Arnold D; Minami H; Tabernero J; Douillard JY
Ann Oncol; 2019 Jan; 30(1):19-33. PubMed ID: 30475956
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial.
Hu H; Kang L; Zhang J; Wu Z; Wang H; Huang M; Lan P; Wu X; Wang C; Cao W; Hu J; Huang Y; Huang L; Wang H; Shi L; Cai Y; Shen C; Ling J; Xie X; Cai Y; He X; Dou R; Zhou J; Ma T; Zhang X; Luo S; Deng W; Ling L; Liu H; Deng Y
Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):38-48. PubMed ID: 34688374
[TBL] [Abstract][Full Text] [Related]
14. Expert consensus on the clinical application of immunotherapy in breast cancer: 2024.
Wang K; Yang J; Wang B; Liu Q; Wang X; Yin Y; Wang H; Wang S; Hao C; Hao X; Liu Y; Jiang Z; ;
Transl Breast Cancer Res; 2024; 5():9. PubMed ID: 38751677
[TBL] [Abstract][Full Text] [Related]
15. Single-Agent Neoadjuvant Immunotherapy With a PD-1 Antibody in Locally Advanced Mismatch Repair-Deficient or Microsatellite Instability-High Colorectal Cancer.
Pei F; Wu J; Zhao Y; He W; Yao Q; Huang M; Huang J
Clin Colorectal Cancer; 2023 Mar; 22(1):85-91. PubMed ID: 36528470
[TBL] [Abstract][Full Text] [Related]
16. [Localized MSI/dMMR gastric cancer patients, perioperative immunotherapy instead of chemotherapy: The GERCOR NEONIPIGA phase II study is opened to recruitment].
Cohen R; Pudlarz T; Garcia-Larnicol ML; Vernerey D; Dray X; Clavel L; Jary M; Piessen G; Zaanan A; Aparicio T; Louvet C; Tournigand C; Chibaudel B; Tougeron D; Guimbaud R; Benouna J; Adenis A; Sokol H; Borg C; Duval A; Svrcek M; André T
Bull Cancer; 2020 Apr; 107(4):438-446. PubMed ID: 32057467
[TBL] [Abstract][Full Text] [Related]
17. [Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2023 edition)].
;
Zhonghua Zhong Liu Za Zhi; 2023 Jul; 45(7):539-574. PubMed ID: 37460438
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant Immunotherapy for MSI-H/dMMR Locally Advanced Colorectal Cancer: New Strategies and Unveiled Opportunities.
Zhang X; Wu T; Cai X; Dong J; Xia C; Zhou Y; Ding R; Yang R; Tan J; Zhang L; Zhang Y; Wang Y; Dong C; Li Y
Front Immunol; 2022; 13():795972. PubMed ID: 35371084
[TBL] [Abstract][Full Text] [Related]
19. [Systematic review of methodological quality and reporting quality in gastric cancer screening guidelines].
Jiang BS; Yao PT; Ge YB; Yang M; Sun X; Ren JS; Chen WQ; Dai M; Li J; Li N
Zhonghua Yu Fang Yi Xue Za Zhi; 2020 Mar; 54(3):314-319. PubMed ID: 32187938
[No Abstract] [Full Text] [Related]
20. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach.
Luchini C; Bibeau F; Ligtenberg MJL; Singh N; Nottegar A; Bosse T; Miller R; Riaz N; Douillard JY; Andre F; Scarpa A
Ann Oncol; 2019 Aug; 30(8):1232-1243. PubMed ID: 31056702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
